MacroGenics Corp (MGNX): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand MacroGenics Corp (MGNX)

The revenue valuation multiple for MacroGenics, Inc. (MGNX) reflects market expectations, where the value of 0.90 serves as the current metric. Investors must account for the risks of clinical trial failures and high capital requirements. MacroGenics, Inc. (MGNX) is integrating AI into antibody design and automating synthesis, while leveraging growing demand in immuno-oncology and partnerships with global behemoths.

MGNX MacroGenics, Inc.: P/S Multiple in the range 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for MacroGenics Corp (MGNX)

- current quotes and average value forecast:
Market Price macrogenics.com|MGNX - Price Target Chart
- stock exchange capitalization data:
Market Value MacroGenics Corp|MGNX - Total Company Value
- book capitalization indicators:
Accounting Value per Share MacroGenics|MGNX - Book Capitalization|Market Capitalization to Book Value Ratio macrogenics.com|MGNX - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio MacroGenics, Inc.|MGNX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MacroGenics Inc.|MGNX - Company Debts|Debts to Book Value MacroGenics Corp|MGNX - Company Long-Term Debts|Short-Term Indebtedness MacroGenics|Immediate Liquidity macrogenics.com
- business earnings and investment ratios data:
MGNX - Company Net Income|Net Profit Forecast MacroGenics, Inc.|MGNX - P/E Multiple|Market Cap to Projected Earnings MacroGenics Inc|MGNX - PEG Multiple|Enterprise Value to EBITDA Ratio MacroGenics Corp|MGNX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters MacroGenics|MGNX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months macrogenics.com|MGNX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year MacroGenics, Inc.
- issuer revenue and sales details:
MGNX - Company Revenue|Company Revenue Forecast macrogenics.com|MGNX - P/S Multiple|Forward Price-to-Revenue Multiple MacroGenics Corp
Fundamental company analysis:MGNX - macrogenics.com
Original product of MacroGenics Inc.

The specifics of MacroGenics, Inc. (MGNX) lie in its high dependence on oncology trial outcomes and external funding. The P/S ratio determines the business value through the ratio of market capitalization to annual sales volume. Analyzing the revenue multiple allows for tracking these proportions in real-time, eliminating reporting time lags. Comparing current values with historical trends helps investors avoid overpaying for speculative optimism.

Competing companies

OLMA - Price to Sales|Price-to-Revenue Ratio Puma Biotechnology, Inc. PBYI|Market Capitalization-to-Revenue Ratio GLSI|ZNTL - Price-to-Revenue Ratio|Plus Therapeutics, Inc. (PSTV) - Market Cap to Revenue|PCSA: P/S Multiple|Eagle Pharmaceuticals, Inc. (EGRX) - P/S Multiple